Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 298.975 -1.36% -4.12
REGN closed up 1.23 percent on Thursday, July 18, 2019, on 65 percent of normal volume.

Earnings due: Aug 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical REGN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.36%
Multiple of Ten Bullish Other -1.36%
Up 3 Days in a Row Strength -1.36%
Up 4 Days in a Row Strength -1.36%
Up 5 Days in a Row Strength -1.36%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.15%
Multiple of Ten Bearish Other -0.15%
Up 3 Days in a Row Strength -0.15%
Up 4 Days in a Row Strength -0.15%
Narrow Range Bar Range Contraction 0.20%

Older signals for REGN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Medicine Biotechnology Health Biopharmaceutical Pain Immunology Infectious Diseases Antibodies Monoclonal Antibodies Inflammation Disorders Rheumatoid Arthritis Cardiovascular Diseases Atopic Dermatitis Macular Edema Sanofi Breakthrough Therapy Allergic Asthma Immune Diseases Metastatic Colorectal Cancer Regeneron
Is REGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 442.0
52 Week Low 287.66
Average Volume 846,472
200-Day Moving Average 365.5347
50-Day Moving Average 308.0078
20-Day Moving Average 307.406
10-Day Moving Average 300.27
Average True Range 9.3105
ADX 18.02
+DI 17.0967
-DI 20.9862
Chandelier Exit (Long, 3 ATRs ) 299.8985
Chandelier Exit (Short, 3 ATRs ) 315.5915
Upper Bollinger Band 324.6093
Lower Bollinger Band 290.2027
Percent B (%b) 0.37
BandWidth 11.19256
MACD Line -3.9874
MACD Signal Line -3.5548
MACD Histogram -0.4326
Fundamentals Value
Market Cap 32.14 Billion
Num Shares 106 Million
EPS 9.97
Price-to-Earnings (P/E) Ratio 30.40
Price-to-Sales 8.43
Price-to-Book 7.99
PEG Ratio 1.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 313.59
Resistance 3 (R3) 312.79 308.50 311.84
Resistance 2 (R2) 308.50 305.82 308.90 311.26
Resistance 1 (R1) 305.79 304.17 307.15 306.59 310.67
Pivot Point 301.50 301.50 302.17 301.90 301.50
Support 1 (S1) 298.79 298.82 300.15 299.59 295.51
Support 2 (S2) 294.50 297.17 294.90 294.92
Support 3 (S3) 291.79 294.50 294.34
Support 4 (S4) 292.59